Abstrakt

Przypisy

• 1. Al-Shraim M., Asa S.L.: The 2004 World Health organization classificationof pituitary tumors: what is new? Acta Neuropathol., 2006;111: 1-7
  Google Scholar
• 2. Botelho C.H., Magalhães A.V., Mello P.A., Schmitt F.C., CasulariL.A.: Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq. Neuropsiquiatr.,2006; 64: 60-66
  Google Scholar
• 3. Dworakowska D., Grossman A.B.: The pathophysiology of pituitaryadenomas. Best Pract. Res. Clin. Endocrinol. Metab., 2009;23: 525-541
  Google Scholar
• 4. Karapetian R.N., Evstafieva A.G., Abaeva I.S., Chichkova N.V., FilonovG.S., Rubtsov Y.P., Sukhacheva E.A., Melnikov S.V., Schneider U.,Wanker E.E., Vartapetian A.B.: Nuclear oncoprotein prothymosin α isa partner of Keap1: implications for expression of oxidative stressprotectinggenes. Mol. Cell. Biol., 2005; 25: 1089-1099
  Google Scholar
• 5. Knosp E., Steiner E., Kitz K., Matula C.: Pituitary adenomas withinvasion of the cavernous sinus space: a magnetic resonance imagingclassification compared with surgical findings. Neurosurgery,1993; 33: 610-617
  Google Scholar
• 6. Marek Ł.: The role of the apoptosome in the activation of procaspase-9.Postępy Hig. Med. Dośw., 2013; 67: 54-64
  Google Scholar
• 7. Mastronardi L., Guiducci A., Puzzilli F.: Lack of correlation betweenKi-67 labelling index and tumor size of anterior pituitaryadenomas. BMC Cancer, 2001; 1: 12
  Google Scholar
• 8. Mete O., Ezzat S., Asa S.L.: Biomarkers of aggressive pituitaryadenomas. J. Mol. Endocrinol., 2012; 49: R69-R78
  Google Scholar
• 9. Oktar N.: Controversies and innovations in the new WHO classificationof pituitary adenomas. J. Neurol. Sci. Turk., 2006; 23: 68-69 10 Ortiz L.D., Syro L.V., Scheithauer B.W., Rotondo F., Uribe H.,Fadul C.E., Horvath E., Kovacs K.: Temozolomide in aggressive pituitaryadenomas and carcinomas. Clinics, 2012; 67 (Suppl. 1): 119-123
  Google Scholar
• 10. years of experience with the German Pituitary Tumor Registry.Eur. J. Endocrinol., 2007; 156: 203-216
  Google Scholar
• 11. Pasquel F.J., Vincenti C., Brat D.J., Oyesiku N.M., IoachimescuA.G.: Pituitary carcinoma in situ. Endocr. Pract., 2013; 19: e69-e73
  Google Scholar
• 12. Pawlikowski M., Radek M., Kunert-Radek J., Jaranowska M.,Świętosławski J., Winczyk K.: Overexpression of prothymosin alphais related to pituitary adenoma recurrence but not to adenomainvasiveness and proliferation. Endokrynol. Pol., 2014; 65: 382-386References
  Google Scholar
• 13. Pawlikowski M., Winczyk K.: Immunohistochemical detection ofprothymosin alpha in pituitary adenomas – a new marker of tumorrecurrence? Folia Histochem. Cytobiol., 2009; 47: 559-562
  Google Scholar
• 14. Saeger W., Lüdecke D.K., Buchfelder M., Fahlbusch R., QuabbeH.J., Petersenn S.: Pathohistological classification of pituitary tumors:
  Google Scholar
• 15. Salehi F., Kovacs K., Scheithauer B.W., Lloyd R.V., Cusimano M.:Pituitary tumor-transforming gene in endocrine and other neoplasms:a review and update. Endocr. Relat. Cancer, 2008; 15: 721-743
  Google Scholar
• 16. Sokołowski G., Bałdys-Waligórska A., Trofimiuk M., Adamek D.,Hubalewska-Dydejczyk A., Gołkowski F.: Expression of cyclooxygenase-2(COX-2) in pituitary tumours. Med. Sci. Monit., 2012; 18:CR252-CR259
  Google Scholar
• 17. Tripathi S.C., Matta A., Kaur J., Grigull J., Chauhan S.S., ThakarA., Shukla N.K., Duggal R., Choudhary A.R., Dattagupta S., SharmaM.C., Ralhan R., Siu K.W.: Overexpression of prothymosin alpha predictspoor disease outcome in head and neck cancer. PLoS One, 2011;6: e19213
  Google Scholar
• 18. TrofimiukMüldner M., Bałdys-Waligórska A., Sokołowski G.,Adamek D., Hubalewska-Dydejczyk A., Gołkowski F.: TopoisomeraseIIα as a prognostic factor in pituitary tumors. Pol. Arch. Med.Wewn., 2014; 124; 500-508
  Google Scholar
• 19. Trouillas J., Roy P., Sturm N., Dantony E., Cortet-Rudelli C., ViennetG., Bonneville J.F., Assaker R., Auger C., Brue T., Cornelius A., DufourH., Jouanneau E., François P., Galland F., et al.: A new prognosticclinicopathological classification of pituitary adenomas: a multicentriccase–control study of 410 patients with 8 years post-operativefollow-up. Acta Neuropathol., 2013; 126: 123-135
  Google Scholar
• 20. Zada G., Lin N., Laws E.R.: Patterns of extrasellar extension ingrowth hormone-secreting and nonfunctional pituitary macroadenomas.Nerosurg. Focus, 2010; 29: 1-5
  Google Scholar
• 21. Zada G., Woodmansee W.W., Ramkissoon S., Amadio J., NoseV., Laws E.R. Jr.: Atypical pituitary adenomas: incidence, clinicalcharacteristics, and implications. J. Neurosurg., 2011; 114: 336-344
  Google Scholar

Pełna treść artykułu